Targeting breast cancer using retinoic acid trifloromethyl chalcone, a promising therapeutic strategy in the treatment of breast cancer

被引：0

作者：

Ding, Hao ^{[1
]}

Wang, Ben-Zhong ^{[2
]}

Zhu, Hua-Qing ^{[3
]}

Dong, Liu-Yi ^{[4
]}

Gu, Yu-Fang ^{[1
]}

Zhao, Yu ^{[1
]}

机构：

[1] Anhui Med Univ, Affiliated Hosp 1, Dept Plast Surg, Hefei 230022, Peoples R China

[2] Anhui Med Univ, Affiliated Hosp 1, Dept Breast Surg, Hefei 230022, Peoples R China

[3] Anhui Med Univ, Dept Biochem, Hefei 230022, Peoples R China

[4] Anhui Med Univ, Dept Pharmacol, Hefei 230022, Peoples R China

来源：

BANGLADESH JOURNAL OF PHARMACOLOGY | 2015年 / 10卷 / 01期

关键词：

7,12-dimethylbenz(a)anthracene; Breast cancer; Chemopreventive; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MAMMARY CARCINOGENESIS; CELLS; CYCLOOXYGENASE; GLIOMA;

D O I：

10.3329/bjp.v10i1.21599

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The study was devised to investigate the effect of retinoic acid trifloromethyl chalcone (RAFC) on mammary carcinogenesis in female rats. The data revealed a significant decrease in number of rats with mammary tumor, number of tumors per rat and tumor volume by 54, 72 and 75% respectively in RAFC group compared to control group. The ibuprofen treated rats also showed a significant decrease in number of rats with tumor, number of tumors per rat and tumor volumes by 43%, 55%, and 59%, respectively. Treatment of rats with RAFC also increased the latency period of tumor induction significantly. Median detection period (50% of tumors) was 92, 83 and 56 days respectively in the rats from RAFC, ibuprofen and control groups respectively after DMBA induction. These results demonstrate that RAFC possesses strong chemopreventive activity against mammary carcinogenesis.

引用

页码：209 / 213

页数：5

共 50 条

[1] Cyclooxygenase-2 knockdown using retinoic acid chalcone (RAC), a promising therapeutic strategy for colon cancer
Jiang, Chao
Wang, Qiong
Xu, Zhe
Li, Wei-Su
Chen, Che
Yao, Xue-Quan
Liu, Fu-Kun
AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (06): : 2012 - 2021
[2] Targeting breast cancer stem cells as a therapeutic strategy
Clarkson, Richard
BREAST CANCER MANAGEMENT, 2014, 3 (03) : 237 - 240
[3] Targeting ErbB2 (neu) Using Transmembrane Peptides is a Promising Novel Therapeutic Strategy for Breast Cancer
Arpel, A.
Baumlin, N.
Cremel, G.
Orend, G.
Laquerriere, P.
Bagnard, D.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : S239 - S239
[4] Therapeutic targeting of breast cancer
Penault-Llorca, Frederique
ANNALES DE PATHOLOGIE, 2009, 29 : S71 - S73
[5] Targeting the immune system as a therapeutic strategy for patients with breast cancer
Gilewski T.
Current Breast Cancer Reports, 2010, 2 (4) : 214 - 221
[6] Promising strategy for a breast cancer vaccine
不详
EXPERT REVIEW OF VACCINES, 2007, 6 (03) : 301 - 301
[7] RANKL inhibition: a promising novel strategy for breast cancer treatment
Gonzalez-Suarez, Eva
CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (04): : 222 - 228
[8] RANKL inhibition: a promising novel strategy for breast cancer treatment
Eva González-Suárez
Clinical and Translational Oncology, 2011, 13 : 222 - 228
[9] Enhanced Delivery of Retinoic Acid to Breast Cancer Cells by Folate Receptor-Targeted Folic Acid-Conjugated Glutenin Nanoparticles for Promising Treatment of Breast Cancer
Rajeshkumar, Raja Rajeswari
Pavadai, Parasuraman
Panneerselvam, Theivendren
Pandian, Sureshbabu Ram Kumar
Kumar, A. Santhana Krishna
Maszczyk, Piotr
Babkiewicz, Ewa
Kabilan, Shanmugampillai Jeyarajaguru
Kunjiappan, Selvaraj
JOURNAL OF POLYMERS AND THE ENVIRONMENT, 2024, 32 (05) : 2120 - 2139
[10] Targeting GPR89 as a novel therapeutic strategy for breast cancer
Ferro, R.
Carroll, A.
Hickman, O.
Vlachogiannis, G.
Trendell, J.
Krastev, D.
Pettitt, S.
Amodeo, V.
Annunziato, S.
Jonkers, J.
Liv, N.
Pardo, M.
Roumeliotis, T. I.
Choudhary, J.
Natrajan, R.
Grigoriadis, A.
Madhusudhan, M. S.
Haider, S.
Lord, C. J.
Tutt, A.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S113 - S113

← 1 2 3 4 5 →